Compounding pharmacies and telehealth companies will ultimately need to stop producing their versions of semaglutide following the resolution of the short-term shortage of the manufacturer’s original brand drug product. Compounding pharmacies were previously allowed to create generic versions of the diabetes and weight loss drug due to supply issues, but with the Food and Drug Administration (FDA) now declaring the shortage over, production and sales must cease by April 22 for pharmacies and May 22 …
Read More